EU ends first pharmaceutical excessive pricing probe
The European Commission has closed its excessive pricing investigation into Aspen, after the drugmaker committed to reduce the price of six of its cancer medicines and continue supplying them across the EU.
To read more
Subscribe to Global Competition Review
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Competition Review experts.